Biotech

Antares announced its 2020 net revenue guidance of US$135 to US$155 million, which includes potential revenue scenarios for AMAG’s Makena.

Antares Pharma (NASDAQ:ATRS) today announced its 2020 full-year net revenue guidance of US$135 to US$155 million, which includes a range of potential revenue scenarios for AMAG’s Makena.

As quoted in the press release:

In addition, the Company also announced that full-year 2019 revenue is expected to be at the upper end or exceed our revenue guidance of $115 to $120 million.

Robert F. Apple, President and Chief Executive Officer of the Company, stated, “We are extremely pleased with the significant commercial progress we made last year driven primarily by increased prescriptions for XYOSTED along with strong and growing demand for Teva’s generic epipen. As a result, we believe 2019 full-year reported revenue will be at the upper end or exceed our guidance range of $115 to $120 million.”

Click here to read the full press release.

MARKETS

Markets
TSX18861.36-217.28
TSXV617.26-9.08
DOW30775.43-253.88
S&P 5003785.38-33.45
NASD11028.74-149.16
ASX6568.10-132.10

COMMODITIES

Commodities
Gold1805.19-1.68
Silver20.21-0.05
Copper3.67-0.04
Palladium1931.50+9.50
Platinum898.00+1.00
Oil106.13+0.37
Heating Oil3.86+0.03
Natural Gas5.72+0.30

DOWNLOAD FREE REPORTS

×